Ignite Creation Date:
2024-05-05 @ 10:23 PM
Last Modification Date:
2024-10-26 @ 10:17 AM
Study NCT ID:
NCT01094067
Status:
TERMINATED
Last Update Posted:
2018-07-09
First Post:
2010-03-25
Brief Title:
Tezosentan in Patients With Pulmonary Arterial Hypertension
Sponsor:
Idorsia Pharmaceuticals Ltd
Organization:
Idorsia Pharmaceuticals Ltd
Study Overview
Official Title:
Multi-center Double-blind Randomized Placebo-controlled Cross-over Study to Demonstrate That a Single Infusion of Tezosentan Has Minimal Effect on Blood Pressure in Patients With Pulmonary Arterial Hypertension Treated With Endothelin Receptor Antagonists Phosphodiesterase-5 Inhibitors or a Combination of Both
Status:
TERMINATED
Status Verified Date:
2018-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Due to slow recruitment the study was prematurely discontinued
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Multicenter double-blind randomized placebo-controlled cross-over study to demonstrate that a single infusion of tezosentan has minimal effect on blood pressure in patients with pulmonary arterial hypertension treated with endothelin receptor antagonists phosphodiesterase-5 inhibitors or a combination of both
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None